Role of advanced glycation endproducts and glyoxalase i in diabetic peripheral sensory neuropathy

Translational Research

Volumn 159, Issue 5, 2012, Pages 355-365

  Jack, Megan ^a   Wright, Douglas ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DICARBONYL DERIVATIVE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENFOTIAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; LACTOYLGLUTATHIONE LYASE; METFORMIN; PIOGLITAZONE; PYRIDOXAMINE; THIAMINE;

CONTINUOUS INFUSION; DETOXIFICATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC DIFFERENCE; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW; RISK FACTOR; SENSORY NEUROPATHY;

EID: 84859711529     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2011.12.004     Document Type: Review

References (129)

1. Centers for Disease Control and Prevention National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States 2011 ed. 2011 U.S. Department of Health and Human Services, Centers for Disease Control and Prevention Atlanta, GA
2. T.L. van Belle, K.T. Coppieters, and M.G. von Herrath Type 1 diabetes: etiology, immunology, and therapeutic strategies Physiol Rev 91 2011 79 118
3. G. Said Diabetic neuropathy - a review Nat Clin Pract Neurol 3 2007 331 340
4. A.J. Boulton, L. Vileikyte, G. Ragnarson-Tennvall, and J. Apelqvist The global burden of diabetic foot disease Lancet 366 2005 1719 1724
5. A.I. Vinik, T.S. Park, K.B. Stansberry, and G.L. Pittenger Diabetic neuropathies Diabetologia 43 2000 957 973
6. J.L. Edwards, A.M. Vincent, H.T. Cheng, and E.L. Feldman Diabetic neuropathy: mechanisms to management Pharmacol Ther 120 2008 1 34
7. A.A. Little, J.L. Edwards, and E.L. Feldman Diabetic neuropathies Pract Neurol 7 2007 82 92
8. D.W. Zochodne, N. Ramji, and C. Toth Neuronal targeting in diabetes mellitus: a story of sensory neurons and motor neurons Neuroscientist 14 2008 311 318
9. DCCT The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N Engl J Med 329 1993 977 986
10. S. Yagihashi, S. Yamagishi, and R. Wada Pathology and pathogenetic mechanisms of diabetic neuropathy: correlation with clinical signs and symptoms Diabetes Res Clin Pract 77 2007 S184 S189
11. G. Said, G. Slama, and J. Selva Progressive centripetal degeneration of axons in small fibre diabetic polyneuropathy Brain 106 1983 791 807
12. R.A. Malik, S. Tesfaye, and P.G. Newrick Sural nerve pathology in diabetic patients with minimal but progressive neuropathy Diabetologia 48 2005 578 585
13. J.M. Kennedy, and D.W. Zochodne Impaired peripheral nerve regeneration in diabetes mellitus J Peripher Nerv Syst 10 2005 144 157
14. J.M. Kennedy, and D.W. Zochodne The regenerative deficit of peripheral nerves in experimental diabetes: its extent, timing and possible mechanisms Brain 123 2000 2118 2129
15. A.M. Vincent, J.W. Russell, P. Low, and E.L. Feldman Oxidative stress in the pathogenesis of diabetic neuropathy Endocr Rev 25 2004 612 628
16. G. Pambianco, T. Costacou, E. Strotmeyer, and T.J. Orchard The assessment of clinical distal symmetric polyneuropathy in type 1 diabetes: a comparison of methodologies from the Pittsburgh Epidemiology of Diabetes Complications Cohort Diabetes Res Clin Pract 92 2011 280 287
17. J.D. England, G.S. Gronseth, and G. Franklin Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation Neurology 64 2005 199 207
18. J.C. Arezzo, and E. Zotova Electrophysiologic measures of diabetic neuropathy: mechanism and meaning Int Rev Neurobiol 50 2002 229 255
19. K.A. Kles, and V. Bril Diagnostic tools for diabetic sensorimotor polyneuropathy Curr Diabetes Rev 2 2006 353 361
20. C. Gibbons, and R. Freeman The evaluation of small fiber function-autonomic and quantitative sensory testing Neurol Clin 22 2004 683 702
21. M. Sinnreich, B.V. Taylor, and P.J. Dyck Diabetic neuropathies. Classification, clinical features, and pathophysiological basis Neurologist 11 2005 63 79
22. D.W. Zochodne Diabetic neuropathies: features and mechanisms Brain Pathol 9 1999 369 391
23. I.G. Obrosova Diabetic painful and insensate neuropathy: pathogenesis and potential treatments Neurotherapeutics 6 2009 638 647
24. L. Sorensen, L. Molyneaux, and D.K. Yue Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycaemic control Diabetes Res Clin Pract 57 2002 45 51
25. K. Sugimoto, Y. Murakawa, and A.A. Sima Diabetic neuropathy - a continuing enigma Diabetes Metab Res Rev 16 2000 408 433
26. S. Tesfaye, and P. Kempler Painful diabetic neuropathy Diabetologia 48 2005 805 807
27. R.A. Malik, A. Veves, and D. Walker Sural nerve fibre pathology in diabetic patients with mild neuropathy: relationship to pain, quantitative sensory testing and peripheral nerve electrophysiology Acta Neuropathol 101 2001 367 374
28. R. Pop-Busui, W.H. Herman, and E.L. Feldman DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history Curr Diab Rep 10 2010 276 282
29. J.W. Albers, W.H. Herman, and R. Pop-Busui Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Diabetes Care 33 2010 1090 1096
30. S. Tesfaye, L.K. Stevens, and J.M. Stephenson Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study Diabetologia 39 1996 1377 1384
31. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group Ann Intern Med 122 1995 561 568
32. C.L. Martin, J. Albers, and W.H. Herman Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion Diabetes Care 29 2006 340 344
33. M. Peppa, P. Stavroulakis, and S.A. Raptis Advanced glycoxidation products and impaired diabetic wound healing Wound Repair Regen 17 2009 461 472
34. P. Ulrich, and A. Cerami Protein glycation, diabetes, and aging Recent Prog Horm Res 56 2001 1 21
35. N. Nass, B. Bartling, and A. Navarrete Santos Advanced glycation end products, diabetes and ageing Z Gerontol Geriatr 40 2007 349 356
36. M.S. Huijberts, N.C. Schaper, and C.G. Schalkwijk Advanced glycation end products and diabetic foot disease Diabetes Metab Res Rev 24 2008 S19 S24
37. R.J. Koenig, C.M. Peterson, and R.L. Jones Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus N Engl J Med 295 1976 417 420
38. K. Kankova Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent? Proc Nutr Soc 67 2008 60 74
39. G. Munch, B. Westcott, T. Menini, and A. Gugliucci Advanced glycation endproducts and their pathogenic roles in neurological disorders Amino Acids 2010 Oct 14 [Epub ahead of print]
40. R. Ramasamy, S.J. Vannucci, and S.S. Yan Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation Glycobiology 15 2005 16R 28R
41. Z. Turk Glycotoxines, carbonyl stress and relevance to diabetes and its complications Physiol Res 59 2010 147 156
42. S.A. Phillips, and P.J. Thornalley The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal Eur J Biochem 212 1993 101 105
43. P.J. Thornalley Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification - a role in pathogenesis and antiproliferative chemotherapy Gen Pharmacol 27 1996 565 573
44. M. Xue, N. Rabbani, and P.J. Thornalley Glyoxalase in ageing Semin Cell Dev Biol 22 2011 293 301
45. P.J. Thornalley Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems - role in ageing and disease Drug Metabol Drug Interact 23 2008 125 150
46. T. Oya, N. Hattori, and Y. Mizuno Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts J Biol Chem 274 1999 18492 18502
47. P.J. Beisswenger, S.K. Howell, R.G. Nelson, M. Mauer, and B.S. Szwergold Alpha-oxoaldehyde metabolism and diabetic complications Biochem Soc Trans 31 2003 1358 1363
48. T.H. Fleming, P.M. Humpert, P.P. Nawroth, and A. Bierhaus Reactive metabolites and AGE/RAGE-mediated cellular dysfunction affect the aging process - a mini-review Gerontology 57 2010 435 443
49. M.A. Mirza, A.J. Kandhro, S.Q. Memon, M.Y. Khuhawar, and R. Arain Determination of glyoxal and methylglyoxal in the serum of diabetic patients by MEKC using stilbenediamine as derivatizing reagent Electrophoresis 28 2007 3940 3947
50. Y. Han, E. Randell, and S. Vasdev Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with Type 1 diabetes Clin Biochem 42 2009 562 569
51. P.J. Beisswenger, K.S. Drummond, and R.G. Nelson Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress Diabetes 54 2005 3274 3281
52. N. Ahmed, R. Babaei-Jadidi, S.K. Howell, P.J. Beisswenger, and P.J. Thornalley Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes Diabetologia 48 2005 1590 1603
53. N. Karachalias, R. Babaei-Jadidi, N. Ahmed, and P.J. Thornalley Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats Biochem Soc Trans 31 2003 1423 1425
54. N. Ahmed Advanced glycation endproducts - role in pathology of diabetic complications Diabetes Res Clin Pract 67 2005 3 21
55. A.W. Stitt AGEs and diabetic retinopathy Invest Ophthalmol Vis Sci 51 2010 4867 4874
56. J.M. Bohlender, S. Franke, G. Stein, and G. Wolf Advanced glycation end products and the kidney Am J Physiol Renal Physiol 289 2005 F645 F659
57. P.J. Thornalley Dicarbonyl intermediates in the Maillard reaction Ann N Y Acad Sci 1043 2005 111 117
58. K.M. Haslbeck, E.D. Schleicher, and U. Friess N(epsilon)- Carboxymethyllysine in diabetic and non-diabetic polyneuropathies Acta Neuropathol 104 2002 45 52
59. I.K. Lukic, P.M. Humpert, P.P. Nawroth, and A. Bierhaus The RAGE pathway: activation and perpetuation in the pathogenesis of diabetic neuropathy Ann N Y Acad Sci 1126 2008 76 80
60. K. Sugimoto, Y. Nishizawa, S. Horiuchi, and S. Yagihashi Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct Diabetologia 40 1997 1380 1387
61. C. Ryle, and M. Donaghy Non-enzymatic glycation of peripheral nerve proteins in human diabetics J Neurol Sci 129 1995 62 68
62. I. Misur, K. Zarkovic, and A. Barada Advanced glycation endproducts in peripheral nerve in type 2 diabetes with neuropathy Acta Diabetol 41 2004 158 166
63. Y. Yu, S.R. Thorpe, and A.J. Jenkins Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes Diabetologia 49 2006 2488 2498
64. R. Meerwaldt, T.P. Links, and R. Graaff Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy Diabetologia 48 2005 1637 1644
65. J.S. Hwang, C.H. Shin, and S.W. Yang Clinical implications of N epsilon-(carboxymethyl)lysine, advanced glycation end product, in children and adolescents with type 1 diabetes Diabetes Obes Metab 7 2005 263 267
66. A. Araszkiewicz, D. Naskret, and P. Niedzwiecki Increased accumulation of skin advanced glycation end products is associated with microvascular complications in type 1 diabetes Diabetes Technol Ther 13 2011 837 842
67. C. Toth, L.L. Rong, and C. Yang Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy Diabetes 57 2008 1002 1017
68. A.M. Vincent, L. Perrone, and K.A. Sullivan Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress Endocrinology 148 2007 548 558
69. A. Bierhaus, K.M. Haslbeck, and P.M. Humpert Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily J Clin Invest 114 2004 1741 1751
70. C. Toth, J. Martinez, and D.W. Zochodne RAGE, diabetes, and the nervous system Curr Mol Med 7 2007 766 776
71. N. Ahmed, and P.J. Thornalley Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 9 2007 233 245
72. R. Ramasamy, S.F. Yan, K. Herold, R. Clynes, and A.M. Schmidt Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis Ann N Y Acad Sci 1126 2008 7 13
73. M. Morcos, X. Du, and F. Pfisterer Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans Aging Cell 7 2008 260 269
74. A.D. Chougale, S.P. Bhat, and S.V. Bhujbal Proteomic analysis of glycated proteins from streptozotocin-induced diabetic rat kidney Mol Biotechnol 2011 Apr 23 [Epub ahead of print]
75. J.D. Mendez, J. Xie, M. Aguilar-Hernandez, and V. Mendez-Valenzuela Molecular susceptibility to glycation and its implication in diabetes mellitus and related diseases Mol Cell Biochem 344 2010 185 193
76. N. Rabbani, and P.J. Thornalley Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome Amino Acids 2010 Oct 21 [Epub ahead of print]
77. H.J. Lee, S.K. Howell, R.J. Sanford, and P.J. Beisswenger Methylglyoxal can modify GAPDH activity and structure Ann N Y Acad Sci 1043 2005 135 145
78. P.J. Beisswenger, S.K. Howell, K. Smith, and B.S. Szwergold Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes Biochim Biophys Acta 1637 2003 98 106
79. A. Riboulet-Chavey, A. Pierron, and I. Durand Methylglyoxal impairs the insulin signaling pathways independently of the formation of intracellular reactive oxygen species Diabetes 55 2006 1289 1299
80. C.G. Schalkwijk, O. Brouwers, and C.D. Stehouwer Modulation of insulin action by advanced glycation endproducts: a new player in the field Horm Metab Res 40 2008 614 619
81. C.F. Bento, F. Marques, R. Fernandes, and P. Pereira Methylglyoxal alters the function and stability of critical components of the protein quality control PLoS One 5 2010 e13007
82. M.A. Queisser, D. Yao, and S. Geisler Hyperglycemia impairs proteasome function by methylglyoxal Diabetes 59 2010 670 678
83. C.G. Schalkwijk, J. van Bezu, and R.C. van der Schors Heat-shock protein 27 is a major methylglyoxal-modified protein in endothelial cells FEBS Lett 580 2006 1565 1570
84. I.E. Scheffler Mitochondria make a come back Adv Drug Deliv Rev 49 2001 3 26
85. X.J. Han, K. Tomizawa, and A. Fujimura Regulation of mitochondrial dynamics and neurodegenerative diseases Acta Med Okayama 65 2011 1 10
86. M.P. Mattson, M. Gleichmann, and A. Cheng Mitochondria in neuroplasticity and neurological disorders Neuron 60 2008 748 766
87. B. Lu Mitochondrial dynamics and neurodegeneration Curr Neurol Neurosci Rep 9 2009 212 219
88. P. Fernyhough, S.K. Roy Chowdhury, and R.E. Schmidt Mitochondrial stress and the pathogenesis of diabetic neuropathy Expert Rev Endocrinol Metab 5 2010 39 49
89. M.G. Rosca, T.G. Mustata, and M.T. Kinter Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation Am J Physiol Renal Physiol 289 2005 F420 F430
90. O. Brouwers, P.M. Niessen, and I. Ferreira Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation endproducts and oxidative stress in diabetic rats J Biol Chem 286 2010 1374 1380
91. M.G. Rosca, V.M. Monnier, L.I. Szweda, and M.F. Weiss Alterations in renal mitochondrial respiration in response to the reactive oxoaldehyde methylglyoxal Am J Physiol Renal Physiol 283 2002 F52 F59
92. N. Rabbani, and P.J. Thornalley Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stress Biochem Soc Trans 36 2008 1045 1050
93. A. Schlotterer, G. Kukudov, and F. Bozorgmehr C. elegans as model for the study of high glucose-mediated life span reduction Diabetes 58 2009 2450 2456
94. E. Zherebitskaya, E. Akude, D.R. Smith, and P. Fernyhough Development of selective axonopathy in adult sensory neurons isolated from diabetic rats: role of glucose-induced oxidative stress Diabetes 58 2009 1356 1364
95. S.K. Chowdhury, E. Zherebitskaya, and D.R. Smith Mitochondrial respiratory chain dysfunction in dorsal root ganglia of streptozotocin-induced diabetic rats and its correction by insulin treatment Diabetes 59 2010 1082 1091
96. E. Akude, E. Zherebitskaya, and S.K. Chowdhury Diminished superoxide generation is associated with respiratory chain dysfunction and changes in the mitochondrial proteome of sensory neurons from diabetic rats Diabetes 60 2011 288 297
97. B. Mannervik Molecular enzymology of the glyoxalase system Drug Metabol Drug Interact 23 2008 13 27
98. E. Racker The mechanism of action of glyoxalase J Biol Chem 190 1951 685 696
99. P.J. Thornalley Glyoxalase I - structure, function and a critical role in the enzymatic defence against glycation Biochem Soc Trans 31 2003 1343 1348
100. B. Kuhla, K. Boeck, and H.J. Luth Age-dependent changes of glyoxalase I expression in human brain Neurobiol Aging 27 2006 815 822
101. P.J. Thornalley The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life Biochem J 269 1990 1 11
102. N. Rabbani, and P.J. Thornalley Glyoxalase in diabetes, obesity and related disorders Semin Cell Dev Biol 22 2011 309 317
103. P.J. Thornalley Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors Chem Biol Interact 111-112 1998 137 151
104. M.M. Jack, J.M. Ryals, and D.E. Wright Characterisation of glyoxalase I in a streptozocin-induced mouse model of diabetes with painful and insensate neuropathy Diabetologia 54 2011 2174 2182
105. M.S. Johnson, J.M. Ryals, and D.E. Wright Early loss of peptidergic intraepidermal nerve fibers in an STZ-induced mouse model of insensate diabetic neuropathy Pain 140 2008 35 47
106. R. Williams, J.E. Lim, and B. Harr A common and unstable copy number variant is associated with differences in Glo1 expression and anxiety-like behavior PLoS One 4 2009 e4649
107. T.A. Graubert, P. Cahan, and D. Edwin A high-resolution map of segmental DNA copy number variation in the mouse genome PLoS Genet 3 2007 e3
108. R. Redon, S. Ishikawa, and K.R. Fitch Global variation in copy number in the human genome Nature 444 2006 444 454
109. R.S. Sparkes, M.C. Sparkes, M. Crist, and C.E. Anderson Glyoxalase I "null" allele in a new family: identification by abnormal segregation pattern and quantitative assay Hum Genet 64 1983 146 147
110. C.P. Gale, T.S. Futers, and L.K. Summers Common polymorphisms in the glyoxalase-1 gene and their association with pro-thrombotic factors Diab Vasc Dis Res 1 2004 34 39
111. C.P. Gale, and P.J. Grant The characterisation and functional analysis of the human glyoxalase-1 gene using methods of bioinformatics Gene 340 2004 251 260
112. M. Barua, E.C. Jenkins, and W. Chen Glyoxalase I polymorphism rs2736654 causing the Ala111Glu substitution modulates enzyme activity - implications for autism Autism Res 4 2011 262 270
113. J.C. Wu, X.H. Li, and Y.D. Peng Association of two glyoxalase 1 gene polymorphisms with nephropathy and retinopathy in type 2 diabetes J Endocrinol Invest 2011 Jul 7 [Epub ahead of print]
114. M. Shinohara, P.J. Thornalley, and I. Giardino Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis J Clin Invest 101 1998 1142 1147
115. U. Ahmed, D. Dobler, S.J. Larkin, N. Rabbani, and P.J. Thornalley Reversal of hyperglycemia-induced angiogenesis deficit of human endothelial cells by overexpression of glyoxalase 1 in vitro Ann N Y Acad Sci 1126 2008 262 264
116. O. Brouwers, P.M. Niessen, and G. Haenen Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress Diabetologia 53 2010 989 1000
117. M.H. Gangadhariah, M. Mailankot, L. Reneker, and R.H. Nagaraj Inhibition of methylglyoxal-mediated protein modification in glyoxalase I overexpressing mouse lenses J Ophthalmol 2010 2010 274317
118. A.G. Miller, D.G. Smith, M. Bhat, and R.H. Nagaraj Glyoxalase I is critical for human retinal capillary pericyte survival under hyperglycemic conditions J Biol Chem 281 2006 11864 11871
119. L. Velez, G. Sokoloff, K.A. Miczek, A.A. Palmer, and S.C. Dulawa Differences in aggressive behavior and DNA copy number variants between BALB/cJ and BALB/cByJ substrains Behav Genet 40 2010 201 210
120. J.K. Sun, H.A. Keenan, and J.D. Cavallerano Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-year medalist study Diabetes Care 34 2011 968 974
121. A. Vinik The question is, my dear Watson, why did the dog not bark? The Joslin 50-year medalist study Diabetes Care 34 2011 1060 1063
122. W.K. Bolton, D.C. Cattran, and M.E. Williams Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy Am J Nephrol 24 2004 32 40
123. B.I. Freedman, J.P. Wuerth, and K. Cartwright Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II) Control Clin Trials 20 1999 493 510
124. M.E. Williams, W.K. Bolton, and R.G. Khalifah Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy Am J Nephrol 27 2007 605 614
125. I. Kanazawa, M. Yamamoto, T. Yamaguchi, and T. Sugimoto Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus Exp Clin Endocrinol Diabetes 119 2011 362 365
126. L. Engelen, S.S. Lund, and I. Ferreira Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes Eur J Endocrinol 164 2011 371 379
127. K. Desai, and L. Wu Methylglyoxal and advanced glycation endproducts: new therapeutic horizons? Recent Pat Cardiovasc Drug Discov 2 2007 89 99
128. S.F. Yan, R. Ramasamy, and A.M. Schmidt Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging Biochem Pharmacol 79 2010 1379 1386
129. P. Maher, R. Dargusch, and J.L. Ehren Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes PLoS One 6 2011 e21226